scholarly journals Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

2015 ◽  
Vol 16 (7) ◽  
pp. 816-829 ◽  
Author(s):  
Sara A Hurvitz ◽  
Fabrice Andre ◽  
Zefei Jiang ◽  
Zhimin Shao ◽  
Max S Mano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Multicentre Trial ◽  
Advanced Breast ◽  
Line Treatment ◽  
First Line ◽  
Her2 Positive ◽  
Phase 3 ◽  
Double Blind ◽  
First Line Treatment

scholarly journals Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

BMC Cancer ◽  
2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Stefania Redana ◽  
Michela Donadio ◽  
Franco Nolè ◽  
Maria Elena Jacomuzzi ◽  
Alessandra Beano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Line Treatment ◽  
First Line ◽  
Her2 Positive ◽  
Retrospective Comparison ◽  
First Line Treatment

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

2014 ◽  
Vol 15 (6) ◽  
pp. 580-591 ◽  
Author(s):  
Fabrice André ◽  
Ruth O'Regan ◽  
Mustafa Ozguroglu ◽  
Masakazu Toi ◽  
Binghe Xu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Her2 Positive ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document